INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
Gossamer Bio, Inc. (GOSS)
Last gossamer bio, inc. earnings: 3/24 07:00 am
Check Earnings Report
Company Research
Source: GlobeNewswire
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Gossamer and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On February 23, 2026, Gossamer announced that its Phase 3 PROSERA trial evaluating seralutinib in pulmonary arterial hypertension failed to meet its primary endpoint. On this news, Gossamer’s stock price fell $1.71 per share, or 80.14%, to close at $0.423 per share on February 23, 2026. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigat
Show less
Read more
Impact Snapshot
Event Time:
GOSS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GOSS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GOSS alerts
High impacting Gossamer Bio, Inc. news events
Weekly update
A roundup of the hottest topics
GOSS
News
- Gossamer Bio (GOSS) had its price target lowered by Oppenheimer Holdings, Inc. from $12.00 to $3.00. They now have an "outperform" rating on the stock.MarketBeat
- GOSS: Management Optimistic About Topline Results -- LEVI & KORSINSKY, LLP Investigates After Trial FailsGlobeNewswire
- GOSS: Announces Topline Results for Phase 3 PROSERA Trial -- LEVI & KORSINSKY, LLPPR Newswire
- GOSS Investors Have Opportunity to Join Gossamer Bio, Inc. Fraud Investigation with the Schall Law FirmBusiness Wire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSSPR Newswire
GOSS
Earnings
- 11/5/25 - Miss
GOSS
Sec Filings
- 3/2/26 - Form SCHEDULE
- 2/24/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- GOSS's page on the SEC website